Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DCVAC/OvCa added to chemotherapy in relapsed platinum-sensitive ovarian cancer
NCT02107950Phase 2Completed
- Sponsor
- SOTIO Biotech
- Start
- Nov 2013
- Primary completion
- Nov 2016
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial in epithelial ovarian carcinoma (EOC) comparing DCVAC/OvCa + Chemotherapy with Standard of Care (2 arms). Primary endpoint: Progression Free Survival at 72 weeks. Started Nov 2013; status: completed.
02
Drugs
DCVAC/OvCa
03
Conditions
epithelial ovarian carcinoma (EOC)
Beyond the preview
Go deeper on NCT02107950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02107950.